54gene provides a genetics testing platform that utilizes next-generation sequencing technology to analyze DNA samples for genetic variations. This service enables healthcare providers to identify hereditary conditions and tailor personalized treatment plans, improving patient outcomes in genetic healthcare.

AN2 Therapeutics develops boron-based compounds aimed at creating first-in-class therapeutics for infectious diseases and oncology. Their approach addresses the need for novel treatment options in these critical areas of global health.

This company develops small molecule antiviral drugs targeting infections caused by HPV, herpes viruses, HIV, and animal retroviruses. Their medicinal chemistry platform aims to create direct-acting antivirals, helping patients recover from viral diseases.

The company provides a High‑Definition PCR (HDPCR™) platform that delivers over four‑fold multiplexing of DNA and RNA biomarkers using standard PCR instruments, enabling comprehensive genomic profiling without dedicated hardware. Its cloud‑based analytics suite automates assay interpretation, quality control, and reporting in a HIPAA‑ and ISO‑compliant environment, offering a faster, lower‑cost alternative to NGS for oncology, MRD, and disease‑monitoring applications in clinical laboratories.

Curevo is a clinical-stage biotech firm developing adjuvanted subunit vaccines to enhance immune responses against infectious diseases. Their approach aims to improve vaccine efficacy and safety, addressing the need for more effective immunization strategies in public health.

The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.

This startup produces fortified packaged food products designed to provide essential nutrition to low and middle-income households in frontier markets. Their offerings specifically target early life and maternal malnutrition by delivering affordable, nutrient-rich options to families facing limited access to healthcare and clean water.

Develops self-adjuvanting, multi-antigen vaccine candidates using a proprietary platform to target antimicrobial-resistant pathogens. This approach addresses the growing threat of untreatable microbial infections by providing preventive solutions with the potential for broad efficacy and reduced reliance on traditional adjuvants.

Memo Therapeutics develops fully human therapeutic antibodies by mining the natural immune responses of elite responders to viral infections and cancer using its proprietary DROPZYLLA® platform. Its lead candidate, potravitug, is a Phase II monoclonal antibody targeting BK polyomavirus in kidney transplant patients, and the company is also pursuing novel oncology antibodies derived from tumor‑infiltrating B‑cell repertoires.

Pulmocide develops opelconazole, an inhaled dry‑powder azole antifungal that delivers 2–3 µm particles deep into the lungs, achieving lung concentrations >2000‑fold higher than plasma. The formulation provides localized treatment and prophylaxis for invasive pulmonary aspergillosis and other Aspergillus‑related lung diseases while minimizing systemic toxicity and drug‑drug interactions. Opelconazole is in a Phase 3 superiority trial and holds FDA orphan, Fast‑Track and QIDP designations.

VitriVax provides a formulation technology platform (ALTA®) that creates thermostable, single‑dose vaccines stable up to 70 °C for months, removing the need for refrigeration and multiple administrations. By combining spray‑drying encapsulation with atomic layer deposition of nanometer‑thin metal‑oxide coatings, the platform enables controlled, sustained release of antigen and adjuvant, supporting scalable manufacturing for vaccine developers, pharma manufacturers, and public‑health agencies targeting remote or resource‑limited settings.

X-VAX is developing mucosal vaccines targeting pathogens like herpes, utilizing advanced adjuvant formulations to enhance immune response at mucosal surfaces. This approach aims to provide effective protection against infections that enter the body through mucosal membranes, addressing a significant gap in current vaccine offerings.